Skip to main content

BIOLOGIA DEL CANCER

SAF2014-57791-REDC

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Redes Investigación /Redes Excelencia
Call year 2014
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Investigación, Desarrollo e Innovación
Beneficiary centre FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III

Resultados relacionados

Resultados totales (Incluyendo duplicados): 36
Encontrada(s) 1 página(s)

Docta Complutense
Publication Artículo científico (JournalArticle)

Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer

  • Álvarez-Fernández, Mónica
  • Sanz-Flores, María
  • Sanz-Castillo, Belén
  • Salazar Roa, María
  • Partida, David
  • Zapatero-Solana, Elisabet
  • Ali, Raza
  • Manchado, Eusebio
  • Lowe, Scott
  • VanArsdale, Todd
  • Shields, David
  • Caldas, Carlos
  • Quintela-Fandino, Miguel
  • Malumbres, Marcos
PP2A is a major tumor suppressor whose inactivation is frequently found in a wide spectrum of human tumors. In particular, deletion or epigenetic silencing of genes encoding the B55 family of PP2A regulatory subunits is a common feature of breast cancer cells. A key player in the regulation of PP2A/B55 phosphatase complexes is the cell cycle kinase MASTL (also known as Greatwall). During cell division, inhibition of PP2A-B55 by MASTL is required to maintain the mitotic state, whereas inactivation of MASTL and PP2A reactivation is required for mitotic exit. Despite its critical role in cell cycle progression in multiple organisms, its relevance as a therapeutic target in human cancer and its dependence of PP2A activity is mostly unknown. Here we show that MASTL overexpression predicts poor survival and shows prognostic value in breast cancer patients. MASTL knockdown or knockout using RNA interference or CRISPR/Cas9 systems impairs proliferation of a subset of breast cancer cells. The proliferative function of MASTL in these tumor cells requires its kinase activity and the presence of PP2A-B55 complexes. By using a new inducible CRISPR/Cas9 system in breast cancer cells, we show that genetic ablation of MASTL displays a significant therapeutic effect in vivo. All together, these data suggest that the PP2A inhibitory kinase MASTL may have both prognostic and therapeutic value in human breast cancer.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

VRK1 chromatin kinase phosphorylates H2AX and is required for foci formation induced by DNA damage

  • Salzano, Marcella
  • Sanz-García, Marta
  • Monsalve, Diana M.
  • Moura, David S.
  • Lazo, Pedro A.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License., All types of DNA damage cause a local alteration and relaxation of chromatin structure. Sensing and reacting to this initial chromatin alteration is a necessary trigger for any type of DNA damage response (DDR). In this context, chromatin kinases are likely candidates to participate in detection and reaction to a locally altered chromatin as a consequence of DNA damage and, thus, initiate the appropriate cellular response. In this work, we demonstrate that VRK1 is a nucleosomal chromatin kinase and that its depletion causes loss of histones H3 and H4 acetylation, which are required for chromatin relaxation, both in basal conditions and after DNA damage, independently of ATM. Moreover, VRK1 directly and stably interacts with histones H2AX and H3 in basal conditions. In response to DNA damage induced by ionizing radiation, histone H2AX is phosphorylated in Ser139 by VRK1. The phosphorylation of H2AX and the formation of gH2AX foci induced by ionizing radiation (IR), are prevented by VRK1 depletion and are rescued by kinase-active, but not kinase-dead, VRK1. In conclusion, we found that VRK1 is a novel chromatin component that reacts to its alterations and participates very early in DDR, functioning by itself or in cooperation with ATM., DMM and M S-G were supported by JAE-CSIC-Fondo Social Europeo fellowships. DSM was supported by a Ministerio de Ciencia e Innovación-FPI predoctoral fellowship. This work was funded by grants from Ministerio de Econom ıa y Competitividad (SAF2010-14935, SAF2013-44810R, SAF2014-57791-REDC) and Consejerıa de Educacion de la Junta de Castilla y Leon (CSI002U14) to PAL., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

VRK1 regulates Cajal body dynamics and protects coilin from proteasomal degradation in cell cycle

  • Cantarero, Lara
  • Sanz-García, Marta
  • Vinograd-Byk, Hadar
  • Renbaum, Paul
  • Levy-Lahad, Ephrat
  • Lazo, Pedro A.
Cajal bodies (CBs) are nuclear organelles associated with ribonucleoprotein functions and RNA maturation. CBs are assembled on coilin, its main scaffold protein, in a cell cycle dependent manner. The Ser-Thr VRK1 (vaccinia-related kinase 1) kinase, whose activity is also cell cycle regulated, interacts with and phosphorylates coilin regulating assembly of CBs. Coilin phosphorylation is not necessary for its interaction with VRK1, but it occurs in mitosis and regulates coilin stability. Knockdown of VRK1 or VRK1 inactivation by serum deprivation causes a loss of coilin phosphorylation in Ser184 and of CBs formation, which are rescued with an active VRK1, but not by kinase-dead VRK1. The phosphorylation of coilin in Ser184 occurs during mitosis before assembly of CBs. Loss of coilin phosphorylation results in disintegration of CBs, and of coilin degradation that is prevented by proteasome inhibitors. After depletion of VRK1, coilin is ubiquitinated in nuclei, which is partly mediated by mdm2, but its proteasomal degradation occurs in cytosol and is prevented by blocking its nuclear export. We conclude that VRK1 is a novel regulator of CBs dynamics and stability in cell cycle by protecting coilin from ubiquitination and degradation in the proteasome, and propose a model of CB dynamics., L. C. and M. S-G. were funded by JAE-CSIC-Fondo Social Europeo fellowships. This work was supported by grants from Ministerio de Ciencia e Innovación (SAF2010-14935), Ministerio de Economía y Competitividad (SAF2013-44810R, SAF2014-57791-REDC), and Junta de Castilla y León-Consejería de Educación (CSI002U14) to P.A.L;and grant (702/13) from the Israel Science Foundation to P.R. and E.L.L., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

VRK1 phosphorylates and protects NBS1 from ubiquitination and proteasomal degradation in response to DNA damage

  • Monsalve, Diana M.
  • Campillo-Marcos, Ignacio
  • Salzano, Marcella
  • Sanz-García, Marta
  • Cantarero, Lara
  • Lazo, Pedro A.
Under a Creative Commons license., NBS1 is an early component in DNA-Damage Response (DDR) that participates in the initiation of the responses aiming to repair double-strand breaks caused by different mechanisms. Early steps in DDR have to react to local alterations in chromatin that are induced by DNA damage. NBS1 participates in the early detection of DNA damage and functions as a platform for the recruitment and assembly of components that are sequentially required for the repair process. In this work we have studied whether the VRK1 chromatin kinase can affect the activation of NBS1 in response to DNA damage induced by ionizing radiation. VRK1 is forming a basal preassembled complex with NBS1 in non-damaged cells. Knockdown of VRK1 resulted in the loss of NBS1 foci induced by ionizing radiation, an effect that was also detected in cell-cycle arrested cells and in ATM (−/−) cells. The phosphorylation of NBS1 in Ser343 by VRK1 is induced by either doxorubicin or IR in ATM (−/−) cells. Phosphorylated NBS1 is also complexed with VRK1. NBS1 phosphorylation by VRK1 cooperates with ATM. This phosphorylation of NBS1 by VRK1 contributes to the stability of NBS1 in ATM (−/−) cells, and the consequence of its loss can be prevented by treatment with the MG132 proteasome inhibitor of RNF8. We conclude that VRK1 regulation of NBS1 contributes to the stability of the repair complex and permits the sequential steps in DDR., D.M.M, M. S-G and L. C. were supported by JAE-CSIC-Fondo Social Europeo fellowships. I. C-M. was supported by Ministerio de Economía y Competitividad-FPI-Fondo Social Europeo fellowship. This work was funded by grants from Ministerio de Economía y Competitividad (SAF2013-44810R; SAF2014-57791-REDC) and Consejería de Educación de la Junta de Castilla y León (CSI002U14 and UIC-017) to P.A.L., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Oncogenic Sox2 regulates and cooperates with VRK1 in cell cycle progression and differentiation

  • Moura, David S.
  • Fernández, Isabel F.
  • Marín-Royo, Gema
  • López-Sánchez, Inmaculada
  • Martín-Doncel, Elena
  • Vega, Francisco M.
  • Lazo, Pedro A.
Sox2 is a pluripotency transcription factor that as an oncogene can also regulate cell proliferation. Therefore, genes implicated in several different aspects of cell proliferation, such as the VRK1 chromatin-kinase, are candidates to be targets of Sox2. Sox 2 and VRK1 colocalize in nuclei of proliferating cells forming a stable complex. Sox2 knockdown abrogates VRK1 gene expression. Depletion of either Sox2 or VRK1 caused a reduction of cell proliferation. Sox2 up-regulates VRK1 expression and both proteins cooperate in the activation of CCND1. The accumulation of VRK1 protein downregulates SOX2 expression and both proteins are lost in terminally differentiated cells. Induction of neural differentiation with retinoic acid resulted in downregulation of Sox2 and VRK1 that inversely correlated with the expression of differentiation markers such as N-cadherin, Pax6, mH2A1.2 and mH2A2. Differentiation-associated macro histones mH2A1.2and mH2A2 inhibit CCND1 and VRK1 expression and also block the activation of the VRK1 promoter by Sox2. VRK1 is a downstream target of Sox2 and both form an autoregulatory loop in epithelial cell differentiation., DSM and IL-S were supported by MINECO-FPI predoctoral fellowships. IFF was supported by JAE-CSIC-Fondo Social Europeo predoctoral fellowship. EM-D was supported by JCyL-Consejería de Educación-Fondo Social Europeo predoctoral fellowship. This work was funded by grants from Ministerio de Economía y Competitividad (SAF2013-44810R, SAF2014-57791-REDC) and Consejería de Educación de la Junta de Castilla y León (CSI002U14 and UIC-017) to P.A.L., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Is lineage decision-making restricted during tumoral reprograming of haematopoietic stem cells?

  • Brown, Geoffrey
  • Sánchez García, Isidro
This is an open-access article distributed under the terms of the Creative Commons Attribution License., Within the past years there have been substantial changes to our understanding of haematopoiesis and cells that initiate and sustain leukemia. Recent studies have revealed that developing haematopoietic stem and progenitor cells are much more heterogeneous and versatile than has been previously thought. This versatility includes cells using more than one route to a fate and cells having progressed some way towards a cell type retaining other lineage options as clandestine. These notions impact substantially on our understanding of the origin and nature of leukemia. An important question is whether leukemia stem cells are as versatile as their cell of origin as an abundance of cells belonging to a lineage is often a feature of overt leukemia. In this regard, we examine the coming of age of the >leukemia stem cell> theory and the notion that leukemia, like normal haematopoiesis, is a hierarchically organized tissue. We examine evidence to support the notion that whilst cells that initiate leukemia have multi-lineage potential, leukemia stem cells are reprogrammed by further oncogenic insults to restrict their lineage decision-making. Accordingly, evolution of a sub-clone of lineage-restricted malignant cells is a key feature of overt leukemia., Research in ISG group is partially supported by FEDER and by MINECO (SAF2012-32810, and Red de Excelencia Consolider OncoBIO SAF2014-57791-REDC), Instituto de Salud Carlos III (PIE14/00066), NIH grant (R01 CA109335-04A1), Junta de Castilla y León (BIO/SA32/14 and CSI001U14), the Fundacion Inocente Inocente, the German Carreras Foundation (DJCLS R13/26) and by the ARIMMORA project (European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 282891). The research leading to these results has also received funding from the People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme FP7/2007-2013 under Research Executive Agency grant agreement № 315902., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Infection exposure is a causal factor in B-cell precursor acute lymphoblastic leukemia as a result of Pax5-inherited susceptibility

  • Martín-Lorenzo, Alberto
  • Hauer, Julia
  • Vicente-Dueñas, Carolina
  • González-Herrero, Inés
  • García-Ramírez, Idoia
  • Blanco, Óscar
  • Mayado, Andrea
  • Orfao, Alberto
  • De Las Rivas, Javier
  • Cobaleda, César
  • García-Cenador, Begoña
  • García-Criado, Francisco Javier
  • Sánchez García, Isidro
  • Borkhardt, Arndt
Earlier in the past century, infections were regarded as the most likely cause of childhood B-cell precursor acute lymphoblastic leukemia (pB-ALL). However, there is a lack of relevant biologic evidence supporting this hypothesis. We present in vivo genetic evidence mechanistically connecting inherited susceptibility to pB-ALL and postnatal infections by showing that pB-ALL was initiated in Pax5 heterozygous mice only when they were exposed to common pathogens. Strikingly, these murine pB-ALLs closely resemble the human disease. Tumor exome sequencing revealed activating somatic, nonsynonymous mutations of Jak3 as a second hit. Transplantation experiments and deep sequencing suggest that inactivating mutations in Pax5 promote leukemogenesis by creating an aberrant progenitor compartment that is susceptible to malignant transformation through accumulation of secondary Jak3 mutations. Thus, treatment of Pax5 leukemic cells with specific JAK1/3 inhibitors resulted in increased apoptosis. These results uncover the causal role of infection in pB-ALL development. [Significance]: These results demonstrate that delayed infection exposure is a causal factor in pB-ALL. Therefore, these findings have critical implications for the understanding of the pathogenesis of leukemia and for the development of novel therapies for this disease., J. Hauer has been supported by the German Children’s Cancer Foundation and from the “Forschungskommission” of the medical faculty of the Heinrich Heine University and the “Strategischer Forschungsfond” of the Heinrich Heine University. S. Ginzel has been supported by a scholarship from the Hochschule Bonn-Rhein-Sieg. A. Borkhardt has been supported by the German Children’s Cancer Foundation and the Federal Ministry of Education and Research, Bonn, Germany. Funding to S.N. Constantinescu from Salus Sanguinis, Fondation contre le cancer Belgium; Interuniversity Attraction Poles IAP, and ARC 10/15-027 is acknowledged. Research in the I. Sánchez-García group is partially supported by FEDER and MINECO (SAF2012-32810 and Red de Excelencia Consolider OncoBIO SAF2014-57791-REDC), Instituto de Salud Carlos III (PIE14/00066), Junta de Castilla y León (BIO/SA32/14 , BIO/SA51/15, and CSI001U14), Fundacion Inocente Inocente, and the ARIMMORA project [European Union’s Seventh Framework Programme (FP7/2007- 2013) under grant agreement no. 282891]. The I. Sánchez-García lab is a member of the EuroSyStem and the DECIDE Network funded by the European Union under the FP7 program. A. Borkhardt and I. SánchezGarcía have been supported by the German Carreras Foundation (DJCLS R13/26). Research in the C. Vicente-Dueñas group is partially supported by a “Miguel Servet” Grant (CP14/00082 - AES 2013-2016) from the Instituto de Salud Carlos III (Ministerio de Economía y Competitividad). Research at C. Cobaleda’s lab was partially supported by FEDER, Fondo de Investigaciones Sanitarias (PI13/00160 and PI14/00025), and from an institutional grant from the Fundacion Ramon Areces. A. MartínLorenzo was supported by FSE-Conserjería de Educación de la Junta de Castilla y León (CSI001-13)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Tesis doctoral (DoctoralThesis)

Implicación de la quinasa humana VRK1 en la formación de los cuerpos de Cajal y sus implicaciones patológicas

  • Cantarero, Lara
Memoria presentada por la licenciada en biología Lara Cantarero Abad para optar al grado de doctor por la Universidad de Salamanca, y realizada en el Instituto de Biología Molecular y Celular del Cáncer., Las atrofias musculares espinales (AME) y ataxias son un grupo de enfermedades neurodegenerativas que causan la muerte a edades muy tempranas. Numerosos genes están implicados en dichas patologías, siendo su mecanismo de acción a nivel molecular aún desconocido. La mutación mejor caracterizada y causante de la AME de tipo I es la del gen SMN1 (survival motor neuron 1). SMN es una proteína que se localiza en el citosol, formando parte del complejo SMN, y que se acumula en los Cuerpos de Cajal (CBs) interaccionando con la Coilina. La Coilina es la proteína marcadora de los CBs y es regulada por fosforilación (se han descrito al menos 11 residuos fosforilables) y metilación. Recientemente se han identificado cuatro mutaciones en la quinasa humana VRK1 (R358X,R89Q, R133C y V236M) causantes de hipoplasia pontocerebelosa de tipo 1 y patologías sensoriomotoras hereditarias que cursan con ataxia y debilidad musculares y acaban provocando la muerte a edades muy tempranas. La mutación mejor caracterizada es la R358X, que codifica para una proteína truncada, deslocalizándose del núcleo debido a la pérdida de su región C-terminal. Además, se ha descrito como VRK1 interacciona y fosforila a la Coilina en el residuo serina 184. En este trabajo de tesis doctoral mostramos como la fosforilación de la Coilina por la quinasa humana VRK1 es crucial para la correcta formación de los Cuerpos de Cajal; el silenciamiento de dicha quinasa produce la desintegración y desaparición de estos suborgánulos nucleares. Este efecto es debido, en un primer momento, a la desoligomerización de la coilina, que deja de estar presente en complejos de alto peso molecular. Posteriormente, hemos descrito como la coilina se ubiquitina, a través de la ubiquitina ligasa Mdm2, en el núcleo, para posteriormente ser exportada al citosol donde se degradará en el proteasoma. Este dato es importante debido a que se ha detectado una posible señal de exporte nuclear por primera vez en esta proteína. Además, el silenciamiento de VRK1, provoca una salida masiva de SMN al citosol debido al desensamblaje de los CBs. Esta salida se recupera al inhibir el exporte nuclear con leptomicina B. Adicionalmente, hemos visto que la quinasa VRK1 regula transcripcionalmente a SMN, por algún mecanismo aún desconocido. Sin embargo, no afecta a la inetracción entre SMN y el factor de transcripción p53 o a la estabilidad de SMN. Finalmente, en este trabajo hemos estudiado y caracterizado a todos los mutantes de VRK1 causantes de patologías neurodegenerativas. Hemos visto que el mutante R89Q presenta una mayor actividad quinasa, reflejada en una mayor autofosforilación y fosforilación de sustratos conocidos como p53 o coilina. Sin embargo, los mutantes R133C y R358X, son prácticamente igual de inactivos a la quinasa inactiva K179E, de forma que no tienen capacidad de autofosforilarse ni de fosforilar sustratos. Por último, el mutante V236M, es igual de activo a la quinasa silvestre. Además, este grado de actividad de los distintos mutantes se refleja también en su estabilidad, de tal forma que los más activos son más estables, mientras que las mutaciones que generan quinasas más inactivas son también más inestables. Cabe destacar que todos los mutantes interaccionan tanto con la Coilina como con SMN de igual manera. Así, estudios previos describen a VRK1 como una proteína importante en cáncer; ahora se nos presenta con un nuevo papel implicándose en patologías neurodegenerativas, siendo quizás importante su interacción con otras proteínas y sus posibles efectos., Esta memoria ha sido realizada siendo LARA CANTARERO ABAD beneficiaria de una beca pre-doctoral JAE-Fondo Social Europeo del Consejo Superior de Investigaciones Científicas (CSIC) para la realización de la tesis doctoral (2011-2015). La investigación en el laboratorio ha sido financiada por los siguientes proyectos: Ministerio de Educación y Ciencia, CONSOLIDER-INGENIO2010 (CSD- 007-0017); Ministerio de Ciencia e Innovación (SAF2010-14935); Junta de Castilla y León, Consejería de Educación (CSI006A11-2); CSIC-Hebrew University of Jerusalem, Shaare-Zedek Medical Center, Israel (Ref: PA1003032); Ministerio de Economía y Competitividad (SAF2013-44810R); Ministerio de Economía y Competitividad (SAF2014-57791-REDC); Junta de Castilla y León, Consejería de Educación (CSI002U14)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Could vitamin D analogues be used to target leukemia stem cells?

  • García-Ramírez, Idoia
  • Martín-Lorenzo, Alberto
  • González-Herrero, Inés
  • Rodríguez-Hernández, Guillermo
  • Vicente-Dueñas, Carolina
  • Sánchez García, Isidro
Leukemic stem cells (LSCs) are defined as cells that possess the ability to self-renew and give rise to the differentiated cancer cells that comprise the tumor. These LSCs seem to show chemo-resistance and radio-resistance leading to the failure of conventional cancer therapies. Current therapies are directed at the fast growing tumor mass leaving the LSC fraction untouched. Eliminating LSCs, the root of cancer origin and recurrence, is considered to be a hopeful approach to improve survival or even to cure cancer patients. In order to achieve this, the characterization of LSCs is a prerequisite in order to develop LSC-based therapies to eliminate them. Here we review if vitamin D analogues may allow an avenue to target the LSCs., Research in Isidro Sánchez-García group is partially supported by FEDER and by MINECO (SAF2012-32810, SAF2015-64420-R, and Red de Excelencia Consolider OncoBIO SAF2014-57791-REDC), Instituto de Salud Carlos III (PIE14/00066), ISCIII-Plan de Ayudas IBSAL 2015 Proyectos Integrados (IBY15/00003), by Junta de Castilla y León (BIO/SA51/15, CSI001U14, and UIC-017), by the German Carreras Foundation (DJCLS R13/26), Fundacion Inocente Inocente, and by the ARIMMORA project (European Union’s Seventh Framework Programme (FP7/2007–2013) under grant agreement no. 282891). Isidro Sánchez-García lab is a member of the EuroSyStem and the DECIDE Network funded by the European Union under the FP7 program. Research in Carolina Vicente-Dueñas group is partially supported by a “Miguel Servet” Grant (CP14/00082-AES 2013–2016 FEDER) from the Instituto de Salud Carlos III (Ministerio de Economía y Competitividad). Guillermo Rodriguez-Hernández and Alberto Martín-Lorenzo were supported by FSE-Conserjería de Educación de la Junta de Castilla y León., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

GEMMs addressing Pax5 loss-of-function in childhood pB-ALL

  • Auer, Franziska
  • Ingenhag, Deborah
  • Bhatia, Sanil
  • Enczmann, Jürgen
  • Cobaleda, César
  • Sánchez García, Isidro
  • Borkhardt, Arndt
  • Hauer, Julia
Germline mutations in transcription factors, which are implicated in hematopoiesis in general or specifically in B-cell differentiation have recently been described to confer an inherited risk to pB-ALL with often reduced penetrance. Predicting leukemia development, therapy response and long term follow up of mutation carriers is challenging because experience from large patient cohorts and their long term follow up are not available.Genetically Engineered Murine Models (GEMMs) represent a promising approach to create individualized and precise models reproducing the molecular makeup of the human disease. This review focuses on PAX5 loss-of-function and summarizes techniques of murine model generation, available GEMMs, which mimic Pax5 loss-of-function in leukemia development and discusses the challenges and drawbacks of these models. These aspects are discussed in the context of creating a robust model, which serves not only for validation of the relevance of a genomic alteration in pB-ALL but at the same time as a valid preclinical model., J.H. has been supported by the German Children’s Cancer Foundation (110997) and from the “Forschungskommission” of the medical faculty of the Heinrich Heine University and the “Strategischer Forschungsfond” of the Heinrich-Heine-University. A.B. has been supported by the German Children's Cancer Foundation and the Federal Ministry of Education and Research, Bonn, Germany. A.B. has been supported by the German Carreras Foundation (DJCLS R13/26). Research in ISG group is partially supported by FEDER and by MINECO (SAF2012-32810, and Red de Excelencia Consolider OncoBIO SAF2014-57791-REDC), Instituto de Salud Carlos III (PIE14/00066), National Institutes of Health grant (R01 CA109335-04A1), Junta de Castilla y León (BIO/SA32/14, BIO/SA51/15 and CSI001U14), and the Fundacion Inocente Inocente. Research at CC's lab is partially supported by FEDER, ISCIII (PI13/00160 and PI14/00025) and Fundación Inocente Inocente., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Post-transcriptional modifications contribuye to the overexpression of cyclin D2 in multiple myeloma

  • Misiewicz-Krzeminska, Irena
  • Sarasquete, María Eugenia
  • Vicente-Dueñas, Carolina
  • Krzemiński, Patryk
  • Wiktorska, Katarzyna
  • Corchete, Luis A.
  • Quwaider, Dalia
  • Rojas, Elizabeta A.
  • Corral, Rocío
  • Martín, Ana-África
  • Escalante, Fernando
  • Bárez, Abelardo
  • García, Juan L.
  • Sánchez García, Isidro
  • García-Sanz, Ramón
  • San Miguel, Jesús F.
  • Gutiérrez, Norma Carmen
[Purpose]: Dysregulation of one of the three D-cyclin genes has been observed in virtually all multiple myeloma tumors. The mechanisms by which CCND2 is upregulated in a set of multiple myeloma are not completely deciphered. We investigated the role of post-transcriptional regulation through the interaction between miRNAs and their binding sites at 3′UTR in CCND2 overexpression in multiple myeloma. [Experimental Design]: Eleven myeloma cell lines and 45 primary myeloma samples were included in the study. Interactions between miRNAs deregulated in multiple myeloma and mRNA targets were analyzed by 3′UTR-luciferase plasmid assay. The presence of CCND2 mRNA isoforms different in length was explored using qRT-PCR, Northern blot, mRNA FISH, and 3′ rapid amplification of cDNA ends (RACE)-PCR. [Results]: We detected the presence of short CCND2 mRNA, both in the multiple myeloma cell lines and primary cells. The results obtained by 3′RACE experiments revealed that changes in CCND2 3′UTR length are explained by alternative polyadenylation. The luciferase assays using plasmids harboring the truncated CCND2 mRNA strongly confirmed the loss of miRNA sites in the shorter CCND2 mRNA isoform. Those multiple myelomas with greater abundance of the shorter 3′UTR isoform were associated with significant higher level of total CCND2 mRNA expression. Furthermore, functional analysis showed significant CCND2 mRNA shortening after CCND1 silencing and an increased relative expression of longer isoform after CCND1 and CCND3 overexpression, suggesting that cyclin D1 and D3 could regulate CCND2 levels through modifications in polyadenylation-cleavage reaction. [Conclusions]: Overall, these results highlight the impact of CCND2 3′UTR shortening on miRNA-dependent regulation of CCND2 in multiple myeloma., This study was partially supported by Instituto de Salud Carlos III (Fondo de Investigaciones Sanitarias: PI08/0568 and PI13/00111), Asociacion Española Contra el Cancer (AECC, GCB120981SAN), >Gerencia Regional de Salud, Junta de Castilla y Leon> (GRS 702/A/11, BIO/SA57/13 and BIO/SA35/14) grants, the Spanish Myeloma Network Program (RD12/0036/0058) and the INNOCAMPUS Program (CEI10-1-0010). I. Misiewicz-Krzeminska was supported by Instituto de Salud Carlos III (PS09/01897). M.E. Sarasquete was supported by Contrato Miguel Servet (CP13/00080). Research in the I. Sanchez-García group was supported by FEDER and MINECO (SAF2012-32810, and Red de Excelencia Consolider OncoBIO SAF2014-57791-REDC), Instituto de Salud Carlos III (PIE14/00066), NIH (R01 CA109335-04A1), >Junta de Castilla y Leon> (BIO/SA32/14 and CSI001U14) grants, the Fundacion Inocente Inocente, the German Carreras Foundation (DJCLS R13/26) and by the ARIMMORA project (European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 282891). Research in the C.V. Duenas group was supported by >Miguel Servet> Grant (CP14/00082 AES 2013-2016) from the Instituto de Salud Carlos III (Ministerio de Economía y Competitividad). I. Sanchez-García is an API lab of the EuroSyStem project and a partner within the Marie Curie Initial Training Network DECIDE., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Prolonged intracellular accumulation of light-inducible nanoparticles in leukemia cells allows their remote activation

  • Boto, Carlos
  • Quartin, Emanuel
  • Cai, Yijun
  • Martín-Lorenzo, Alberto
  • García-Cenador, Begoña
  • Pinto, Sandra
  • Gupta, Rajeev
  • Enver, Tariq
  • Sánchez García, Isidro
  • Hong, Dengli
  • Pires das Neves, Ricardo
  • Ferreira, Lino
Leukaemia cells that are resistant to conventional therapies are thought to reside in protective niches. Here, we describe light-inducible polymeric retinoic acid (RA)-containing nano-particles (NPs) with the capacity to accumulate in the cytoplasm of leukaemia cells for several days and release their RA payloads within a few minutes upon exposure to blue/UV light. Compared to NPs that are not activated by light exposure, these NPs more efficiently reduce the clonogenicity of bone marrow cancer cells from patients with acute myeloid leukaemia (AML) and induce the differentiation of RA-low sensitive leukaemia cells. Importantly, we show that leukaemia cells transfected with light-inducible NPs containing RA can engraft into bone marrow in vivo in the proximity of other leukaemic cells, differentiate upon exposure to blue light and release paracrine factors that modulate nearby cells. The NPs described here offer a promising strategy for controlling distant cell populations and remotely modulating leukaemic niches., The authors would like to thank the financial support of FEDER through the programme COMPETE and by Portuguese funds through FCT (PTDC/CTM-NAN/120552/2010 and UID/NEU/04539/2013 to R.P.N.), FCT (SFRH/BD/62419/2009 to C.B.; SFRH/BD/90964/2012 to E.Q.; POCI-01-0145-FEDER-016390:CANCEL STEM to L.F.), EC (ERC project n° 307384, ‘Nanotrigger’ to L.F.), MINECO (SAF2012-32810, SAF2015-64420-R and Red de Excelencia Consolider OncoBIO SAF2014-57791-REDC to I.S.-G.) and Bloodwise and CRUK programme grants to T.E., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Modeling the process of childhood ETV6-RUNX1 B-cell leukemias

  • Rodríguez-Hernández, Guillermo
  • Schäfer, Daniel
  • Gavilán, Ana
  • Vicente-Dueñas, Carolina
  • Hauer, Julia
  • Borkhardt, Arndt
  • Sánchez García, Isidro
ETV6-RUNX1 is associated with the most common subtype of childhood leukemia. Pre-leukaemic clones carrying ETV6-RUNX1 oncogenic lesions are frequently found in neonatal cord blood, but only few ETV6-RUNX1 carriers develop pB-ALL. The highly demanding and pending challenge is to reveal the multistep natural history of ETV6-RUNX1 pB-ALL, because it can offer non-toxic prophylactic interventions to preleukemic carriers. However, the lack of a genetically engineered ETV6-RUNX1 mouse model mimicking the human pB-ALL has hampered our understanding of the pathogenesis of this disease. This rule has now been broken in a study of the effect of the ETV6-RUNX1 oncogene in cancer development in a mouse model in which oncogene expression is restricted to the stem cell compartment. In this article, we review the different attempts to model this disease, including the recent representative success stories and we discuss its potential application to both identify etiologic factors of childhood ETV6-RUNX1 pB-ALL and prevent the conversion of a preleukemic clone in an irreversible transformed state., J.H. has been supported by the German Children’s Cancer Foundation, DJCLS 02R/2016, KKS A2016/07 and from the “Forschungskommission” of the medical faculty of the Heinrich Heine University. A.B. has been supported by the German Children’s Cancer Foundation and the Federal Ministry of Education and Research, Bonn, Germany. Funding to S.N.C. from Salus Sanguinis, Fondation contre le cancer Belgium; Interuniversity Attraction Poles IAP and ARC 10/15-027 is acknowledged. Research in ISG group is partially supported by FEDER and by MINECO (SAF2012-32810, SAF2015-64420-R and Red de Excelencia Consolider OncoBIO SAF2014-57791-REDC), Instituto de Salud Carlos III (PIE14/00066), ISCIII- Plan de Ayudas IBSAL 2015 Proyectos Integrados (IBY15/00003), by Junta de Castilla y León (BIO/SA51/15, CSI001U14, UIC017, and CSI001U16), and by the Fundacion Inocente Inocente. ISG lab is a member of the EuroSyStem and the DECIDE Network funded by the European Union under the FP7 program. A.B. and ISG have been supported by the German Carreras Foundation (DJCLS R13/26). Research in CVD group is partially supported by a “Miguel Servet” Grant (CP14/00082 - AES 2013-2016 - FEDER) from the Instituto de Salud Carlos III (Ministerio de Economía y Competitividad) and by the Lady Tata International Award for Research in Leukaemia 2016–2017., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Infection exposure promotes ETV6-RUNX1 precursor B-cell leukemia via impaired H3K4 demethylases

  • Rodríguez-Hernández, Guillermo
  • Hauer, Julia
  • Martín-Lorenzo, Alberto
  • Schäfer, Daniel
  • Bartenhagen, Christoph
  • García-Ramírez, Idoia
  • Auer, Franziska
  • González-Herrero, Inés
  • Ruiz-Roca, Lucía
  • Gombert, Michael
  • Okpanyi, Vera
  • Fischer, Ute
  • Chen, Cai
  • Dugas, Martin
  • Bhatia, Sanil
  • Martin Linka, René
  • García Suquía, Marta
  • Rascón-Trincado, María Victoria
  • García-Sánchez, Angel
  • Blanco, Óscar
  • García-Cenador, Begoña
  • García-Criado, Francisco Javier
  • Cobaleda, César
  • Alonso-López, D.
  • De Las Rivas, Javier
  • Müschen, Markus
  • Vicente-Dueñas, Carolina
  • Sánchez García, Isidro
  • Borkhardt, Arndt
ETV6-RUNX1 is associated with the most common subtype of childhood leukemia. As few ETV6-RUNX1 carriers develop precursor B-cell acute lymphocytic leukemia (pB-ALL), the underlying genetic basis for development of full-blown leukemia remains to be identified, but the appearance of leukemia cases in time-space clusters keeps infection as a potential causal factor. Here, we present in vivo genetic evidence mechanistically connecting preleukemic ETV6-RUNX1 expression in hematopoetic stem cells/precursor cells (HSC/PC) and postnatal infections for human-like pB-ALL. In our model, ETV6-RUNX1 conferred a low risk of developing pB-ALL after exposure to common pathogens, corroborating the low incidence observed in humans. Murine preleukemic ETV6-RUNX1 pro/preB cells showed high Rag1/2 expression, known for human ETV6-RUNX1 pB-ALL. Murine and human ETV6-RUNX1 pB-ALL revealed recurrent genomic alterations, with a relevant proportion affecting genes of the lysine demethylase (KDM) family. KDM5C loss of function resulted in increased levels of H3K4me3, which coprecipitated with RAG2 in a human cell line model, laying the molecular basis for recombination activity. We conclude that alterations of KDM family members represent a disease-driving mechanism and an explanation for RAG off-target cleavage observed in humans. Our results explain the genetic basis for clonal evolution of an ETV6-RUNX1 preleukemic clone to pB-ALL after infection exposure and offer the possibility of novel therapeutic approaches., J. Hauer has been supported by the German Children's Cancer Foundation, DJCLS 02R/2016, KKS A2016/07 and from the “Forschungskommission” of the medical faculty of the Heinrich Heine University. M. Müschen is an HHMI Faculty Scholar (HHMI-55108547) and supported by NIH/NCI through an Outstanding Investigator Award (R35CA197628) to M. Müschen, a Wellcome Trust Senior Investigator Award, the Leukemia and Lymphoma Society, the California Institute for Regenerative Medicine, the William Lawrence and Blanche Hughes Foundation. A. Borkhardt has been supported by the German Children's Cancer Foundation and the Federal Ministry of Education and Research, Bonn, Germany. Research in I. Sánchez-García's group is partially supported by FEDER and by MINECO (SAF2012-32810, SAF2015-64420-R and Red de Excelencia Consolider OncoBIOSAF2014-57791-REDC), Instituto de Salud Carlos III (PIE14/00066), ISCIII- Plan de Ayudas IBSAL 2015 Proyectos Integrados (IBY15/00003), by Junta de Castilla y León (BIO/SA51/15, CSI001U14, UIC-017, and CSI001U16), Fundacion Inocente Inocente and by the ARIMMORA project (European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 282891). I. Sánchez-García's lab is a member of the EuroSyStem and the DECIDE Network funded by the European Union under the FP7 program. A. Borkhardt and I. Sánchez-García have been supported by the German Carreras Foundation (DJCLS R13/26). Research in C. Vicente-Dueñas' group is partially supported by a “Miguel Servet” grant (CP14/00082-AES 2013-2016-FEDER) from the Instituto de Salud Carlos III (Ministerio de Economía y Competitividad) and by the Lady Tata International Award for Research in Leukaemia 2016–2017. A. Martín-Lorenzo and G. Rodríguez-Hernández were supported by FSE-Conserjería de Educación de la Junta de Castilla y León (CSI001-13 and CSI001-15, respectively)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice

  • García-Ramírez, Idoia
  • Tadros, Saber
  • González-Herrero, Inés
  • Martín-Lorenzo, Alberto
  • Rodríguez-Hernández, Guillermo
  • Moore, Dalia
  • Ruiz-Roca, Lucía
  • Blanco, Óscar
  • Alonso-López, D.
  • De Las Rivas, Javier
  • Hartert, Keenan
  • Duval, Romain
  • Klinkebiel, David
  • Bast, Martin
  • Vose, Julie
  • Lunning, Matthew
  • Fu, Kai
  • Greiner, Timothy
  • Rodrigues-Lima, Fernando
  • Jiménez, Rafael
  • García-Criado, Francisco Javier
  • García-Cenador, Begoña
  • Brindle, Paul
  • Vicente-Dueñas, Carolina
  • Alizadeh, Ash A.
  • Sánchez García, Isidro
  • Green, Michael R.
CREBBP is targeted by inactivating mutations in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). Here, we provide evidence from transgenic mouse models that Crebbp deletion results in deficits in B-cell development and can cooperate with Bcl2 overexpression to promote B-cell lymphoma. Through transcriptional and epigenetic profiling of these B cells, we found that Crebbp inactivation was associated with broad transcriptional alterations, but no changes in the patterns of histone acetylation at the proximal regulatory regions of these genes. However, B cells with Crebbp inactivation showed high expression of Myc and patterns of altered histone acetylation that were localized to intragenic regions, enriched for Myc DNA binding motifs, andshowedMycbinding. Through the analysis ofCREBBPmutations from a large cohort of primary human FL and DLBCL, we show a significant difference in the spectrum of CREBBP mutations in these 2 diseases, with higher frequencies of nonsense/ frameshift mutations in DLBCL compared with FL. Together, our data therefore provide important links between Crebbp inactivation and Bcl2 dependence and show a role for Crebbp inactivation in the induction of Myc expression. We suggest this may parallel the role of CREBBP frameshift/nonsense mutations in DLBCL that result in loss of the protein, but may contrast the role of missense mutations in the lysine acetyltransferase domain that are more frequently observed in FL and yield an inactive protein., Research in the M.R.G. group is supported by grants from the Nebraska Department of Health and Human Services (LB506 2016-16) and the National Institutes of Health, National Cancer Institute (1R01CA201380). Research in the I.S.-G. group is partially supported by Fondo Europeo de Desarrollo Regional (FEDER) and by the Ministry of Economy and Competitiveness (SAF2012-32810, SAF2015-64420-R, and Red de Excelencia Consolider OncoBIO SAF2014-57791-REDC), Instituto de Salud Carlos III (PIE14/00066), Instituto de Salud Carlos III Plan de Ayudas Institute of Biomedical Research of Salamanca 2015 Proyectos Integrados (IBY15/00003), by Junta de Castilla y Leon (BIO/SA51/15, CSI001U14, UIC-017, andCSI001U16), Fundacion Inocente Inocente, by the German Carreras Foundation (Organisation der Deutsche Jose Carreras Leukamie-Stiftung eV R13/26), and by the Advanced Research on Interaction Mechanisms of electro Magnetic Exposures with Organisms for Risk Assessment project (European Union’s Seventh Framework Programme [FP7/2007-2013] under grant agreement no. 282891). The Nebraska Lymphoma Study Group tissue bank is supported by the Fred & Pamela Buffett Cancer Center’s National Cancer Institute Cancer Center Support Grant (P30CA036727). The I.S.-G. laboratory is a member of the EuroSyStem and the Developing Evidence to Inform Decisions about Effectiveness Network funded by the European Union under the FP7 program. Research in the C.V.-D. group is partially supported by a “Miguel Servet” Grant (CP14/00082, AES 2013-2016, FEDER) from the Instituto de Salud Carlos III (Ministerio de Economia y Competitividad). I.G.-R. was supported by BES-Ministerio de Economia y Competitividad (BES-2013-063789). G.R.-H. and L.R.-R. were supported by Fondo Social Europeo-Consejeria de Educacion de la Junta de Castilla y Leon. R.D. was supported by a fellowship from Region Ile de France (Appel hors DIM 2013). Research in the F.R.-L. group was supported by grants from Universite Paris Diderot, CNRS, Institut National du Cancer (2012-1-PL-BIO), and the Plan Cancer Environnement 2013. Ultrafast liquid chromatography analyses were done on the platform “Bioprofiler” (Unite de Biologie Fonctionnelle et Adaptative)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Activation-induced cytidine deaminase prevents pro-B cell acute lymphoblastic leukemia by functioning as a negative regulator in Rag1 deficient pro-B cells

  • Auer, Franziska
  • Ingenhag, Deborah
  • Pinkert, Stefan
  • Kracker, Sven
  • Hacein-Bey-Abina, Salima
  • Cavazzana, Marina
  • Gombert, Michael
  • Martín-Lorenzo, Alberto
  • Lin, Min-Hui
  • Vicente-Dueñas, Carolina
  • Sánchez García, Isidro
  • Borkhardt, Arndt
  • Hauer, Julia
Activation-induced cytidine deaminase (AID) is essential for somatic hypermutation and class switch recombination in mature B-cells, while AID was also shown to play a role in developing pre-BCR/BCR-positive B-cells of the bone marrow. To further elucidate a potential function of Aid in the bone marrow prior to V(D) J-recombination, we utilized an in vivo model which exerts a B-cell developmental arrest at the pro-B cell stage with low frequencies of pro-B cell acute lymphoblastic leukemia (pro-B ALL) development. Therefore, p19ArfRag1 (AR) mice were crossed with Aid-deficient mice (ARA). Surprisingly, loss of Aid expression in pro-B cells accelerated pro-B ALL incidence from 30% (AR) to 98% (ARA). This effect was Aid dose dependent, since Aid animals of the same background displayed a significantly lower incidence (83%). Furthermore, B-cell-specific Aid up-regulation was observed in Aid-competent pro-B ALLs. Additional whole exome/sanger sequencing of murine pro-B ALLs revealed an accumulation of recurrent somatic Jak3 (p. R653H, p. V670A) and Dnm2 (p. G397R) mutations, which highlights the importance of active IL7R signaling in the pro-B ALL blast cells. These findings were further supported by an enhanced proliferative potential of ARA pro-B cells compared to Aid-competent cells from the same genetic background. In summary, we show that both Aid and Rag1 act as a negative regulators in pro-B cells, preventing pro-B ALL., J. Hauer has been supported by the German Cancer Foundation (110997), DJCLS02R/2016, KKS A2016/07 and from the “Forschungskommission” of the medical faculty of the Heinrich Heine University. A. Borkhardt has been supported by the German Children’s Cancer Foundation and the Federal Ministry of Education and Research, Bonn, Germany. Research in I. Sánchez-García’s group is partially supported by FEDER and by MINECO (SAF2012-32810, SAF2015-64420-R and Red de Excelencia Consolider OncoBIO SAF2014-57791-REDC), Instituto de Salud Carlos III (PIE14/00066), ISCIII- Plan de Ayudas IBSAL 2015 Proyectos Integrados (IBY15/00003), by Junta de Castilla y León (BIO/SA51/15, CSI001 U14, UIC-017, and CSI001U16), Fundacion Inocente Inocente and by the ARIMMORA project (European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 282891). I. Sánchez-García’s lab is a member of the EuroSyStem and the DECIDE Network funded by the European Union under the FP7 program. A. Borkhardt and I. Sánchez-García have been supported by the German Carreras Foundation (DJCLS R13/26). Research in C. Vicente-Dueñas’ group is partially supported by a “Miguel Servet” Grant (CP14/00082 - AES 2013-2016 - FEDER) from the Instituto de Salud Carlos III (Ministerio de Economía y Competitividad) and by the Lady Tata International Award for Research in Leukaemia 2016-2017. A. Martín-Lorenzo was supported by FSE-Conserjería de Educación de la Junta de Castilla y León (CSI001-13)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Tesis doctoral (DoctoralThesis)

Roles of human VRK1 Ser-Thr kinase in the regulation of cell proliferation

  • Moura, David S.
Tesis Doctoral presentada por David da Silva Moura, elaborada en el Programa de Doctorado Biociencias: Biología y Clínica del Cáncer y Medicina Traslacional, y realizada en el Instituto de Biología Molecular y Celular del Cáncer de Salamanca (CSIC-USAL)., Cell proliferation and cell differentiation are different mechanisms occurring at different times of the cell life. However, the regulation of the switch from proliferation to differentiation and the role and fate of proliferation-related proteins are mostly unknown. Cell division is a high-regulated mechanism, involving several kinases, namely Vaccinia-related kinase 1 (VRK1) and Aurora kinase B (AurKB). These kinases assure the correct transmission of genetic information to the newly-formed cells, DNA replication, chromosome segregation and chromatin condensation. VRK1 is the first member of the VRK family and is ubiquitously expressed in all the tissues, especially high-proliferative tissue, including liver and thymus or cancer cells. Therefore, based on VRK1 features and expression, its role has been mostly related to the regulation of cell proliferation, including the regulation of transcription factors involved in cell cycle progression and DNA damage repair pathways, modulation of p53 levels, nuclear envelope assembly, Cajal body (CB) formation and maintenance, and fragmentation of the Golgi apparatus. Apart from these, VRK1 also contributes to the mitotic chromatin condensation through histone H3 phosphorylation, mainly, in the Thr3 residue (H3T3ph). H3T3ph is especially important for the formation, localization and function of the chromosomal passenger complex (CPC) on the centromeres, during mitosis. (see group publications). In turn, AurKB is a member of the aurora kinase family, alongside with AurKA and AurKC. The activity of this family of kinases is fulfilled during mitosis, and therefore, they are mitotic kinases critical for the mitotic regulation of centromere function, chromatin condensation, spindle assembly, chromosome alignment and segregation and, cytokinesis. AurKB is a component of CPC, along with Survivin, Borealin and INCENP and contributes to chromatin condensation, through H3S10 phosphorylation. On the other hand, the transcriptional factor (TF) Sox2, a member of the SRY-related HMG-box family of TFs is a master regulator of pluripotency, proliferation, survival and differentiation of embryonic stem cell (ESC)., Moreover, Yamanaka’s factor Sox2 is a cancer initiating cell biomarker in poorly differentiated or undifferentiated cancers, since these types of cancers have been characterized by many phenotypic traits similar to undifferentiated embryonic stem cells. Indeed, Sox2 is overexpressed in numerous tumors like breast cancer and lung cancer or in cancer cell lines suggesting the enormous oncogenic potential of this TF. It is also important to notice, that Sox2 combines with Oct4 to control cell cycle, through cyclin D1 promoter activation. Finally, also macro-histone H2A (macroH2A) can regulate cell differentiation and cell proliferation. Macro H2A (macroH2A1.1, macroH21.2 and macroH2A2) are histones variant that can replace conventional histone H2A in the nucleosomes, repressing cell proliferation genes and favoring cell differentiation genes. These histone variants change the chromatin conformation, affecting TFs binding and creating de novo activation and repression binding sites. It was also reported that macroH2A variants could regulate VRK1 levels. Initially, we observe that VRK1 is a chromatin kinase, besides its usual nucleo-plasmatic and cytoplasmatic localization, and interacts with the histone H3 by immuprecipitation (IP) and ‘’Pull-down’’ assays in early mitosis. Moreover, VRK1 phosphorylates directly the mitotic H3T3, as observed by kinase assay with cold ATP and phospho-specific antibodies. Next and focusing on VRK1 and AurKB relationship we observed that VRK1 and AurKb inhibits the kinase activity of one another, as observed by kinase assay with radiolabeled ATP. Moreover, increasing doses of VRK1, active or inactive, affected negatively the phosphorylation of AurKB-specific residue S10 on histone H3 in kinase assay with cold ATP. Besides, also increasing doses of AurKB, active and inactive, affected negatively the phosphorylation of H3T3 and the phosphorylation of p53T18 by VRK1. This effect is consequence of the formation of a stable complex between the two protein kinases and independent of any type of phosphorylation of one kinase on another. By IP and ‘’Pull-down’’ assay we observed that transfected VRK1 and transfected AurKB interact, forming a stable complex independent of VRK1 activity. VRK1 interacts with AurKB through both amino and carboxy terminals. The interaction between endogenous VRK1 and AurKB occurs in early mitosis, after cell arrest with nocodazole. Yet, no co-localization between the two kinases was, observed by immunofluorescence (IF). Moreover, VRK1 downregulation affected the localization of AurKB in early mitosis in IF assays. VRK1 downregulation avoids centromeric accumulation of AurKB, leading to a more diffuse distribution on the chromatin. This result is due to the loss of H3T3 phosphorylation, as observed by IF and western blot (WB). Loss of VRK1-dependent H3T3 phosphorylation affects the interaction of AurKB with Histone H3 in IP assays. Regarding VRK1 and reprogramming factors, VRK1 and Sox2 distribution was analyzed by immunohistochemistry on a stratified squamous epithelium and it was observed that Sox2 and VRK1 co-localize in the undifferentiated layers of the epithelium. The same result was observed by IF in several cell lines, such as NTera-2 (NT2), MCF-7 or MDA-MB-231. Moreover, VRK1 and Sox2 interact in IP assay. The interaction occurs between transfected proteins and between endogenous proteins, and it is through both VRK1 amino and carboxy terminals. Sox2 is a phosphorylation target of VRK1 as determined by kinase assay with radiolabelled ATP. Sox2, as a regulator of cell proliferation regulates proliferative genes, including VRK1. SOX2 regulates VRK1 promoter in luciferase assays, increasing, when overexpressed, the RNA and protein levels of the kinase, as observed by qRT-PCR, WB and IF. The result was observed in NT2, MDA-MB-231 and MCF-7 cell line. In turn, VRK1 downregulation increases RNA (qRT-PCR) and protein levels (IF and WB) of Sox2 in NT2, MDA-MB-231 and MCF-7, creating a feedback loop between VRK1 and Sox2. The overexpression of VRK1 produced the opposite result. Furthermore, VRK1 and Sox2 cooperate in the activation of CCND1 gene, in luciferase assays potentiating proliferation. After induction of cell differentiation with retinoic acid, both Sox2 and VRK1 RNA and protein are downregulated and they are absent or significantly down-regulated in terminally differentiated epithelial cells. In terminally differentiated cells, macroH2A variants 1.2 and 2 repress VRK1 and CCND1 gene promoter, as determined by luciferase assay. In conclusion, VRK1 participates in the regulation of cell proliferation, through two new and independent mechanisms. One by actively regulating AurKB and the other by regulating the balance between cell proliferation and cell differentiation., Esta memoria ha sido realizada siendo David da Silva Moura beneficiario de una beca predoctoral Formación de Personal Investigador (FPI; referencia BES2011-046945) del Ministerio de Economía y Competitividad para la realización de la tesis doctoral (2011-2015). La investigación en el laboratorio ha sido financiada por los siguientes proyectos: Ministerio de Educación y Ciencia. CONSOLIDER-INGENIO2010 (CDS-007-0017). Ministerio de Ciencia e Innovación: (SAF2010-14935). Junta de Castilla y León, Consejería de Educación: (CSI006A11-2) - (CSI002U14). Ministerio de Economía y Competitividad: (SAF2013-44810R) - (SAF2014-57791-REDC)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid leukemia

  • Vicente-Dueñas, Carolina
  • González-Herrero, Inés
  • Sehgal, Lalit
  • García-Ramírez, Idoia
  • Rodríguez-Hernández, Guillermo
  • Pintado, Belén
  • Blanco, Óscar
  • García Criado, Francisco Javier
  • García-Cenador, Begoña
  • Green, Michael R.
  • Sánchez García, Isidro
The clonal nature of cancer evolution dictates that all tumor cells carry the same cancer-initiating genetic lesions. However, the latest findings have shown that the mode of action of oncogenes is not homogeneous throughout the developmental history of the tumor. Studies on different types of hematopoietic and solid tumors have shown that the contribution of some oncogenes to cancer development is mediated through the epigenetic reprogramming of the cancer-initiating target cell [1,2,3,4]. Epigenetic reprogramming is therefore a new type of interaction between oncogenes and tumor cells, in which the oncogene primes for cancer development by establishing a new pathological tumor cell identity. The current challenge is to test whether epigenetic remodeling in the absence of the driver oncogene is sufficient for tumorigenesis., Research in CVD group is partially supported by FEDER, “Miguel Servet” Grant (CP14/00082 - AES 2013-2016) from the Instituto de Salud Carlos III (Ministerio de Economía y Competitividad), “Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III” (PI17/00167), and by the Lady Tata International Award for Research in Leukaemia 2016–2017. Research in ISG group is partially supported by FEDER and by MINECO (SAF2012-32810, SAF2015-64420-R and Red de Excelencia Consolider OncoBIO SAF2014-57791- REDC), Instituto de Salud Carlos III (PIE14/00066), ISCIII- Plan de Ayudas IBSAL 2015 Proyectos Integrados (IBY15/00003), by Junta de Castilla y León (BIO/SA51/15, CSI001U14, UIC-017, and CSI001U16), and by the German Carreras Foundation (DJCLS R13/26). ISG lab is a member of the EuroSyStem and the DECIDE Network funded by the European Union under the FP7 program. IGR was supported by BES-Ministerio de Economía y Competitividad (BES2013-063789). GRH was supported by FSE-Conserjería de Educación de la Junta de Castilla y León (CSI001-15).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A Chemical Screen Identifies Compounds Capable of Selecting for Haploidy in Mammalian Cells

  • Olbrich, Teresa
  • Vega-Sendino, María
  • Murga, Matilde
  • Cárcer, Guillermo de
  • Malumbres, Marcos
  • Ortega, Sagrario
  • Ruiz, Sergio
  • Fernández-Capetillo, Óscar
© 2019 The Authors., The recent availability of somatic haploid cell lines has provided a unique tool for genetic studies in mammals. However, the percentage of haploid cells rapidly decreases in these cell lines, which we recently showed is due to their overgrowth by diploid cells present in the cultures. Based on this property, we have now performed a phenotypic chemical screen in human haploid HAP1 cells aiming to identify compounds that facilitate the maintenance of haploid cells. Our top hit was 10-Deacetyl-baccatin-III (DAB), a chemical precursor in the synthesis of Taxol, which selects for haploid cells in HAP1 and mouse haploid embryonic stem cultures. Interestingly, DAB also enriches for diploid cells in mixed cultures of diploid and tetraploid cells, including in the colon cancer cell line DLD-1, revealing a general strategy for selecting cells with lower ploidy in mixed populations of mammalian cells., Research was funded by Fundación Botín, Banco Santander through its Santander Universities Global Division, and by grants from MINECO (SAF2014-57791-REDC and SAF2014-59498-R to O.F.-C., SAF-2013- 44866-R to S.O., and SAF2013-49147-P and SAF2016-80874-P to S.R.; projects that were co-financed with ERDF-EU funds) and the European Research Council (ERC-617840). Research at the G.d.C. laboratory is funded by the AECC Scientific Foundation (LABAE16017DECA).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Lineage choice decisions in B-cell development and leukemia

  • Raboso-Gallego, Javier
  • Casado-García, Ana
  • Rodríguez-Hernández, Guillermo
  • Vicente-Dueñas, Carolina
  • Sánchez García, Isidro
Every tissue in the body is founded by a particular type of cell that is termed stem cell. These cells are generally presumed to be tissue-specific and, as such, are also responsible for maintenance of the tissue throughout the lifespan of an organism. There are two fundamental aspects to the regular behaviour of tissues during their genesis and thereafter. The offspring of stem cells divide in a manner that is controlled to the social benefit of the organism to generate/ensure the bulk of tissue that is required. These dividing cells mature: they acquire individual characteristics to enable them to perform a unique function within the tissue. Within cancer cells aspects of this normal physiology are distorted. This means the many strands to understanding of the behaviour of normal cells cannot be loosened from the strands of efforts to unravel what goes wrong in cancer., Research in C Vicente-Dueñas group is partially supported by FEDER, “Miguel Servet” Grant (CP14/00082 -AES 2013-2016) from the Instituto de Salud Carlos III (Ministerio de Economía y Competitividad), “Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III” (PI17/00167). Research in I Sánchez-García (ISG) group is partially supported by FEDER and by MINECO (SAF2012-32810, SAF2015-64420-R and Red de Excelencia Consolider OncoBIO SAF2014-57791-REDC), by Junta de Castilla y León (UIC-017, and CSI001U16). ISG lab is a member of the EuroSyStem and the DECIDE Network funded by the European Union under the FP7 program. ISG has been supported by the German Carreras Foundation (DJCLS R13/26). G Rodríguez-Hernández was supported by FSE-Conserjería de Educación de la Junta de Castilla y León (CSI001-15).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Loss of Pax5 exploits sca1-BCR-ABLp190 susceptibility to confer the metabolic shift essential for pB-ALL

  • Martín-Lorenzo, Alberto
  • Auer, Franziska
  • Chan, Lai N.
  • García-Ramírez, Idoia
  • González-Herrero, Inés
  • Rodríguez-Hernández, Guillermo
  • Bartenhagen, Christoph
  • Dugas, Martin
  • Gombert, Michael
  • Ginzel, Sebastian
  • Blanco, Óscar
  • Orfao, Alberto
  • Alonso-López, D.
  • Rivas, Javier de las
  • García-Cenador, Begoña
  • García-Criado, Francisco Javier
  • Müschen, Markus
  • Sánchez García, Isidro
  • Borkhardt, Arndt
  • Vicente-Dueñas, Carolina
  • Hauer, Julia
Preleukemic clones carrying BCR-ABLp190 oncogenic lesions are found in neonatal cord blood, where the majority of preleukemic carriers do not convert into precursor B-cell acute lymphoblastic leukemia (pB-ALL). However, the critical question of how these preleukemic cells transform into pB-ALL remains undefined. Here, we model a BCR-ABLp190 preleukemic state and show that limiting BCR-ABLp190 expression to hematopoietic stem/progenitor cells (HS/PC) in mice (Sca1-BCR-ABLp190) causes pB-ALL at low penetrance, which resembles the human disease. pB-ALL blast cells were BCR-ABL–negative and transcriptionally similar to pro-B/pre-B cells, suggesting disease onset upon reduced Pax5 functionality. Consistent with this, double Sca1-BCR-ABLp190+Pax5+/− mice developed pB-ALL with shorter latencies, 90% incidence, and accumulation of genomic alterations in the remaining wild-type Pax5 allele. Mechanistically, the Pax5-deficient leukemic pro-B cells exhibited a metabolic switch toward increased glucose utilization and energy metabolism. Transcriptome analysis revealed that metabolic genes (IDH1, G6PC3, GAPDH, PGK1, MYC, ENO1, ACO1) were upregulated in Pax5-deficient leukemic cells, and a similar metabolic signature could be observed in human leukemia. Our studies unveil the first in vivo evidence that the combination between Sca1-BCR-ABLp190 and metabolic reprogramming imposed by reduced Pax5 expression is sufficient for pB-ALL development. These findings might help to prevent conversion of BCR-ABLp190 preleukemic cells., J. Hauer has been supported by the German Cancer Aid (Project 110997 and Translational Oncology Program 70112951), the German Jose Carreras Foundation (DJCLS 02R/2016), the Kinderkrebsstiftung (2016/17), and the "Elterninitiative Kinderkrebstiftung e.V." S. Ginzel has been supported by a scholarship of the Hochschule Bonn-Rhein-Sieg. M. Muschen is an HHMI Faculty Scholar (HHMI- € 55108547) and supported by NIH/NCI through an Outstanding Investigator Award (R35CA197628, R01CA137060, R01CA157644, R01CA172558, R01CA213138) to M. Muschen, a Wellcome Trust Senior Investigator Award, € the Leukemia and Lymphoma Society, the Norman and Sadie Lee Foundation (for Pediatric Cancer, to M. Muschen), and the Dr. Ralph and Marian € Falk Medical Research Trust (to M. Muschen), Cancer Research Institute € through a Clinic and Laboratory Integration Program grant (to M. Muschen) € and the California Institute for Regenerative Medicine (CIRM) through DISC2-10061. A. Borkhardt has been supported by the German Children's Cancer Foundation and the Federal Ministry of Education and Research, Bonn, Germany. Research in I. Sanchez-García's group is partially supported by FEDER and by MINECO (SAF2012-32810, SAF2015-64420-R, and Red de Excelencia Consolider OncoBIO SAF2014-57791-REDC), Instituto de Salud Carlos III (PIE14/00066), ISCIII- Plan de Ayudas IBSAL 2015 Proyectos Integrados (IBY15/00003), by Junta de Castilla y Leon (BIO/SA51/15, CSI001U14, UIC-017, and CSI001U16), Fundacion Inocente Inocente and by the ARIMMORA project [European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 282891]. I. Sanchez-García's lab is a member of the EuroSyStem and the DECIDE Network funded by the European Union under the FP7 program. A. Borkhardt and I. Sanchez-García have been supported by the German Carreras Foundation (DJCLS R13/26). Research in C. Vicente-Duenas's ~ group is partially supported by FEDER, Ministerio de Economía y Competitividad ("Miguel Servet" Grant - CP14/00082 - AES 2013-2016) and (PI17/00167) from the Instituto de Salud Carlos III. A. Martín-Lorenzo and G. Rodríguez-Hernandez were supported by FSE-Conserjería de Educacion de la Junta de Castilla y Leon (CSI001-13 and CSI001-15, respectively). F. Auer was supported by a Deutsche Forschungsgemeinschaft (DFG) fellowship (AU 525/1-1).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Lmo2 expression defines tumor cell identity during T-cell leukemogenesis

  • García-Ramírez, Idoia
  • Bhatia, Sanil
  • Rodríguez-Hernández, Guillermo
  • González-Herrero, Inés
  • Walter, Carolin
  • González de Tena-Dávila, Sara
  • Parvin, Salma
  • Haas, Oskar
  • Woessmann, Wilhelm
  • Stanulla, Martin
  • Schrappe, Martin
  • Dugas, Martin
  • Natkunam, Yasodha
  • Orfao, Alberto
  • Domínguez, Verónica
  • Pintado, Belén
  • Blanco, Óscar
  • Alonso-López, D.
  • Rivas, Javier de las
  • Martín-Lorenzo, Alberto
  • Jiménez, Rafael
  • García-Criado, Francisco Javier
  • García-Cenador, Begoña
  • Lossos, Izidore S.
  • Vicente-Dueñas, Carolina
  • Borkhardt, Arndt
  • Hauer, Julia
  • Sánchez García, Isidro
The impact of LMO2 expression on cell lineage decisions during T-cell leukemogenesis remains largely elusive. Using genetic lineage tracing, we have explored the potential of LMO2 in dictating a T-cell malignant phenotype. We first initiated LMO2 expression in hematopoietic stem/progenitor cells and maintained its expression in all hematopoietic cells. These mice develop exclusively aggressive human-like T-ALL. In order to uncover a potential exclusive reprogramming effect of LMO2 in murine hematopoietic stem/progenitor cells, we next showed that transient LMO2 expression is sufficient for oncogenic function and induction of T-ALL. The resulting T-ALLs lacked LMO2 and its target-gene expression, and histologically, transcriptionally, and genetically similar to human LMO2-driven T-ALL. We next found that during T-ALL development, secondary genomic alterations take place within the thymus. However, the permissiveness for development of T-ALL seems to be associated with wider windows of differentiation than previously appreciated. Restricted Cre-mediated activation of Lmo2 at different stages of B-cell development induces systematically and unexpectedly T-ALL that closely resembled those of their natural counterparts. Together, these results provide a novel paradigm for the generation of tumor T cells through reprogramming in vivo and could be relevant to improve the response of T-ALL to current therapies., J.H. has been supported by the German Cancer Aid (Project 110997 and Translational Oncology Program 70112951), the German Jose Carreras Leukemia Foundation (DJCLS 02R/2016), Deutsches Konsortium für Translationale Krebsforschung (DKTK), Joint funding (Targeting MYC L*10), the Kinderkrebsstiftung (2016/17), and the “Elterninitiative Kinderkrebsklinik e.V. Düsseldorf”. SG has been supported by a scholarship of the Hochschule Bonn-Rhein-Sieg. AB has been supported by the German Children's Cancer Foundation and the Federal Ministry of Education and Research, Bonn, Germany. Research in ISG group is partially supported by FEDER and by MINECO (SAF2012-32810, SAF2015-64420-R, and Red de Excelencia Consolider OncoBIO SAF2014-57791-REDC), Instituto de Salud Carlos III (PIE14/00066), ISCIII- Plan de Ayudas IBSAL 2015 Proyectos Integrados (IBY15/00003), by Junta de Castilla y León (BIO/SA51/15, CSI001U14, UIC-017, and CSI001U16), Fundacion Inocente Inocente, and by the ARIMMORA project (European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 282891). ISG Lab is a member of the EuroSyStem and the DECIDE Network funded by the European Union under the FP7 program. AB and ISG have been supported by the German Carreras Foundation (DJCLS R13/26). IGR was supported by BES-Ministerio de Economía y Competitividad (BES-2013-063789). AML and GRH were supported by FSE-Conserjería de Educación de la Junta de Castilla y León (CSI001-13, CSI001-15). Research in CVD group is partially supported by FEDER, “Miguel Servet” Grant (CP14/00082—AES 2013-2016) from the Instituto de Salud Carlos III (Ministerio de Economía y Competitividad), “Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III” (PI17/00167), and by the Lady Tata International Award for Research in Leukaemia 2016–2017.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

T-cell leukemogenesis is an inappropriate lineage decision-making process: implications for precision oncology

  • Rodríguez-Hernández, Guillermo
  • Bhatia, Sanil
  • Vicente-Dueñas, Carolina
  • Borkhardt, Arndt
  • Hauer, Julia
  • Sánchez García, Isidro
Genetic lineage tracing in cell type-specific mouse models of T-cell acute lymphoblastic leukemia (T-ALL) have revealed that tumor cell identity is imposed by expression of the oncogene Lim Domain Only 2 (LMO2), rather than by the target cell phenotype. This approach allowed to identify that secondary genomic alterations, like Notch1 mutations, appeared late and only took place within the thymus during T-ALL development. These concepts are therefore critical for the development of modern therapies aimed at curing T-ALL., This work was supported by the the German Cancer Aid (Project 110997 and Translational Oncology Program 70112951); German Carreras Foundation; [DJCLS 02R/2016]; the Kinderkrebsstiftung (2016/17); Elterninitiative Kinderkrebsklinik e.V. Düsseldorf; German Children’s Cancer Foundation; Federal Ministry of Education and Research; FEDER; MINECO; [SAF2012-32810]; [SAF2015-64420-R]; [SAF2014-57791-REDC]; Junta de Castilla y León; [BIO/SA51/15]; [CSI001U14]; [UIC-017]; [CSI001U16]; European Union; German Carreras Foundation; [DJCLS R13/26]; FSE-Conserjería de Educación de la Junta de Castilla y León; [CSI001-15]; FEDER, “Miguel Servet”; [CP14/00082 - AES 2013-2016]; Instituto de Salud Carlos III (Ministerio de Economía y Competitividad); Fondo de Investigaciones Sanitarias/ Instituto de Salud Carlos III; [PI17/00167]; Lady Tata International Award for Research in Leukaemia 2016-2017.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The making of leukemia

  • González-Herrero, Inés
  • Rodríguez-Hernández, Guillermo
  • Luengas-Martínez, Andrea
  • Isidro‑Hernández, Marta
  • Jiménez, Rafael
  • García-Cenador, Begoña
  • García-Criado, Francisco Javier
  • Sánchez García, Isidro
  • Vicente-Dueñas, Carolina
© 2018 by the authors., Due to the clonal nature of human leukemia evolution, all leukemic cells carry the same leukemia-initiating genetic lesions, independently of the intrinsic tumoral cellular heterogeneity. However, the latest findings have shown that the mode of action of oncogenes is not homogeneous throughout the developmental history of leukemia. Studies on different types of hematopoietic tumors have shown that the contribution of oncogenes to leukemia is mainly mediated through the epigenetic reprogramming of the leukemia-initiating target cell. This driving of cancer by a malignant epigenetic stem cell rewiring is, however, not exclusive of the hematopoietic system, but rather represents a common tumoral mechanism that is also at work in epithelial tumors. Tumoral epigenetic reprogramming is therefore a new type of interaction between genes and their target cells, in which the action of the oncogene modifies the epigenome to prime leukemia development by establishing a new pathological tumoral cellular identity. This reprogramming may remain latent until it is triggered by either endogenous or environmental stimuli. This new view on the making of leukemia not only reveals a novel function for oncogenes, but also provides evidence for a previously unconsidered model of leukemogenesis, in which the programming of the leukemia cellular identity has already occurred at the level of stem cells, therefore showing a role for oncogenes in the timing of leukemia initiation, We are indebted to all members of our groups for useful discussions and for their critical reading of the manuscript. Research in C.V.-D. group is partially supported by FEDER, “Miguel Servet” Grant (CP14/00082-AES 2013–2016) from the Instituto de Salud Carlos III (Ministerio de Economía y Competitividad), “Fondo de Investigaciones Sanitarias/Instituto de Salud Carlos III” (PI17/00167) and by the Lady Tata International Award for Research in Leukaemia 2016–2017. Research in I.S.G. group is partially supported by FEDER and by MINECO (SAF2012-32810, SAF2015-64420-R and Red de Excelencia Consolider OncoBIO SAF2014-57791-REDC), and by Junta de Castilla y León (UIC-017, and CSI001U16). I.S.G. lab is a member of the EuroSyStem and the DECIDE Network funded by the European Union under the FP7 program. I.S.G. has been supported by the German Carreras Foundation (DJCLS R13/26).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

VRK1 and AURKB form a complex that cross inhibit their kinase activity and the phosphorylation of histone H3 in the progression of mitosis

  • Moura, David S.
  • Campillo-Marcos, Ignacio
  • Vázquez-Cedeira, Marta
  • Lazo, Pedro A.
© The Author(s) 2018., Regulation of cell division requires the integration of signals implicated in chromatin reorganization and coordination of its sequential changes in mitosis. Vaccinia-related kinase 1 (VRK1) and Aurora B (AURKB) are two nuclear kinases involved in different steps of cell division. We have studied whether there is any functional connection between these two nuclear kinases, which phosphorylate histone H3 in Thr3 and Ser10, respectively. VRK1 and AURKB are able to form a stable protein complex, which represents only a minor subpopulation of each kinase within the cell and is detected following nocodazole release. Each kinase is able to inhibit the kinase activity of the other kinase, as well as inhibit their specific phosphorylation of histone H3. In locations where the two kinases interact, there is a different pattern of histone modifications, indicating that there is a local difference in chromatin during mitosis because of the local complexes formed by these kinases and their asymmetric intracellular distribution. Depletion of VRK1 downregulates the gene expression of BIRC5 (survivin) that recognizes H3-T3ph, both are dependent on the activity of VRK1, and is recovered with kinase active murine VRK1, but not with a kinase-dead protein. The H3–Thr3ph–survivin complex is required for AURB recruitment, and their loss prevents the localization of ACA and AURKB in centromeres. The cross inhibition of the kinases at the end of mitosis might facilitate the formation of daughter cells. A sequential role for VRK1, AURKB, and haspin in the progression of mitosis is proposed., This work was funded by grants from Ministerio de Economía y Competitividad (SAF2013-44810-R, SAF2014-57791-REDC), Agencia Estatal de Investigación (SAF2016-75744-R), and Consejería de Educación de la Junta de Castilla y León (CSI001U16 and UIC-17) to P.A.L.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A Single Conserved Residue Mediates Binding of the Ribonucleotide Reductase Catalytic Subunit RRM1 to RRM2 and Is Essential for Mouse Development

  • Specks, Julia
  • Lecona, Emilio
  • López-Contreras, Andrés J.
  • Fernández-Capetillo, Óscar
The ribonucleotide reductase (RNR) complex, composed of a catalytic subunit (RRM1) and a regulatory subunit (RRM2), is thought to be a rate-limiting enzymatic complex for the production of nucleotides. In humans, the Rrm1 gene lies at 11p15.5, a tumor suppressor region, and RRM1 expression in cancer has been shown to predict responses to chemotherapy. Nevertheless, whether RRM1 is essential in mammalian cells and what the effects of its haploinsufficiency are remain unknown. To model RNR function in mice we used a mutation previously described in Saccharomyces cerevisiae (Rnr1-W688G) which, despite being viable, leads to increased interaction of the RNR complex with its allosteric inhibitor Sml1. In contrast to yeast, homozygous mutant mice carrying the Rrm1 mutation (Rrm1WG/WG) are not viable, even at the earliest embryonic stages. Proteomic analyses failed to identify proteins that specifically bind to the mutant RRM1 but revealed that, in mammals, the mutation prevents RRM1 binding to RRM2. Despite the impact of the mutation, Rrm1WG/+ mice and cells presented no obvious phenotype, suggesting that the RRM1 protein exists in excess. Our work reveals that binding of RRM1 to RRM2 is essential for mammalian cells and provides the first loss-of-function model of the RNR complex for genetic studies., This research was funded by Fundación Botín, by Banco Santander through its Santander Universities Global Division, and by grants from the Spanish Ministry of Economy and Competitiveness (MINECO; grants SAF2011-23753 and SAF2014-57791-REDC), Worldwide Cancer Research (12-0229), Fundació La Marato de TV3, Howard Hughes Medical Institute, and the European Research Council (ERC-617840) to O.F.-C., by grants from the Danish Council for Independent Research and the Danish National Research Foundation to A.J.L.-C., and by a Ph.D. fellowship from MINECO to J.S. (BES-2012-05 2030)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

NSMCE2 suppresses cancer and aging in mice independently of its SUMO ligase activity

  • Jacome, Ariana
  • Gutiérrez‐Martínez, Paula
  • Schiavoni, Federica
  • Tenaglia, Enrico
  • Martínez, Paula
  • Rodríguez‐Acebes, Sara
  • Lecona, Emilio
  • Murga, Matilde
  • Méndez, Juan
  • Blasco, María A.
  • Fernández-Capetillo, Óscar
The SMC5/6 complex is the least understood of SMC complexes. In yeast, smc5/6 mutants phenocopy mutations in sgs1, the BLM ortholog that is deficient in Bloom's syndrome (BS). We here show that NSMCE2 (Mms21, in Saccharomyces cerevisiae), an essential SUMO ligase of the SMC5/6 complex, suppresses cancer and aging in mice. Surprisingly, a mutation that compromises NSMCE2‐dependent SUMOylation does not have a detectable impact on murine lifespan. In contrast, NSMCE2 deletion in adult mice leads to pathologies resembling those found in patients of BS. Moreover, and whereas NSMCE2 deletion does not have a detectable impact on DNA replication, NSMCE2‐deficient cells also present the cellular hallmarks of BS such as increased recombination rates and an accumulation of micronuclei. Despite the similarities, NSMCE2 and BLM foci do not colocalize and concomitant deletion of Blm and Nsmce2 in B lymphocytes further increases recombination rates and is synthetic lethal due to severe chromosome mis‐segregation. Our work reveals that SUMO‐ and BLM‐independent activities of NSMCE2 limit recombination and facilitate segregation; functions of the SMC5/6 complex that are necessary to prevent cancer and aging in mice., The authors want to thank Jordi Torres and Mark O'Driscoll for comments on the manuscript. Work in OF laboratory related to this project was supported by Fundación Botín, by Banco Santander through its Santander Universities Global Division and by grants from MINECO (SAF2011‐23753 and SAF2014‐57791‐REDC), Howard Hughes Medical Institute, and the European Research Council (ERC‐617840). Work in JM laboratory was funded by a grant from MINECO (BFU2013‐49153P)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Efficacy of ATR inhibitors as single agents in Ewing sarcoma

  • Nieto-Soler, María
  • Morgado-Palacín, Isabel
  • Lafarga, Vanesa
  • Lecona, Emilio
  • Murga, Matilde
  • Callen, Elsa
  • Azorín, Daniel
  • Alonso, Javier
  • López-Contreras, Andrés J.
  • Nussenzweig, Andre
  • Fernández-Capetillo, Óscar
Ewing sarcomas (ES) are pediatric bone tumors that arise from a driver translocation, most frequently EWS/FLI1. Current ES treatment involves DNA damaging agents, yet the basis for the sensitivity to these therapies remains unknown. Oncogene-induced replication stress (RS) is a known source of endogenous DNA damage in cancer, which is suppressed by ATR and CHK1 kinases. We here show that ES suffer from high endogenous levels of RS, rendering them particularly dependent on the ATR pathway. Accordingly, two independent ATR inhibitors show in vitro toxicity in ES cell lines as well as in vivo efficacy in ES xenografts as single agents. Expression of EWS/FLI1 or EWS/ERG oncogenic translocations sensitizes non-ES cells to ATR inhibitors. Our data shed light onto the sensitivity of ES to genotoxic agents, and identify ATR inhibitors as a potential therapy for Ewing Sarcomas., We would want to thank Enrique de Alava for providing ES lines. Work in O.F. laboratory was supported by Fundación Botín, by Banco Santander through its Santander Universities Global Division and by grants from MINECO (SAF2014-57791-REDC and SAF2014- 59498-R), Fundació La Marato de TV3, Howard Hughes Medical Institute and the European Research Council (ERC-617840). The A.N. laboratory was supported by the Intramural Research Program of the NIH, the National Cancer Institute, the Center for Cancer Research, an Ellison Medical Foundation Senior Scholar in Aging, and the Alex Lemonade Stand Foundation Award. J.A. laboratory is supported by Asociación Pablo Ugarte, ASION-La Hucha de Tomás, Fundación La Sonrisa de Alex and Instituto de Salud Carlos III (PI12/00816 and Spanish Cancer Network RTICC RD12/0036/0027). A.L. laboratory was supported by the Danish National Research Foundation (DNRF115), Danish Council for Independent Research (Sapere Aude, DFF-Starting Grant 2014) and Danish Cancer Society (KBVU-2014)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

USP7 is a SUMO deubiquitinase essential for DNA replication

  • Lecona, Emilio
  • Rodríguez-Acebes, Sara
  • Specks, Julia
  • López-Contreras, Andrés J.
  • Ruppen, Isabel
  • Murga, Matilde
  • Muñoz, Javier
  • Méndez, Juan
  • Fernández-Capetillo, Óscar
Post-translational modification of proteins by ubiquitin (Ub) and Ub-like modifiers regulates DNA replication. We have previously shown that chromatin around replisomes is rich in SUMO and poor in Ub, whereas mature chromatin exhibits an opposite pattern. How this SUMO-rich, Ub-poor environment is maintained at sites of DNA replication in mammalian cells remains unexplored. Here we identify USP7 as a replisome-enriched SUMO deubiquitinase that is essential for DNA replication. By acting on SUMO and SUMOylated proteins, USP7 counteracts their ubiquitination. Inhibition or genetic deletion of USP7 leads to the accumulation of Ub on SUMOylated proteins, which are displaced away from replisomes. Our findings provide a model explaining the differential accumulation of SUMO and Ub at replication forks and identify an essential role of USP7 in DNA replication that should be considered in the development of USP7 inhibitors as anticancer agents., Research was funded by Fundación Botín, Banco Santander, through its Santander Universities Global Division, and by grants from the Spanish Ministry of Economy and Competitiveness (MINECO) (SAF2011-23753 and SAF2014-57791-REDC), Worldwide Cancer Research (12-0229), Fundació La Marato de TV3, the Howard Hughes Medical Institute and the European Research Council (ERC-617840) to O.F.-C.; by a Marie-Curie International Outgoing Fellowship (project no. 235705) from the Seventh Framework Programme for Research and Technological Development, Marie Curie Actions, and a grant from MINECO (BFU2014-55168-JIN) that was cofunded by European Regional Development Funds (FEDER) to E.L.; by grants from the Danish Council for Independent Research and the Danish National Research Foundation to A.J.L.-C.; and by a PhD fellowship from MINECO (BES-2012-05 2030) to J.S. We would like to thank W. Gu (Columbia University) for providing Usp7lox/lox MEFs, J. Chen (MD Anderson Cancer Center) for providing Rad18-deficient HCT116 cells and J. Alegre-Cebollada (Spanish National Center for Cardiovascular Research) for help in the use of PyMOL software., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

POLD3 Is Haploinsufficient for DNA Replication in Mice

  • Murga, Matilde
  • Lecona, Emilio
  • Kamileri, Irene
  • Díaz, Marcos
  • Lugli, Natalia
  • Sotiriou, Sotirios K.
  • Anton, Marta E.
  • Méndez, Juan
  • Halazonetis, Thanos D.
  • Fernández-Capetillo, Óscar
The Pold3 gene encodes a subunit of the Polδ DNA polymerase complex. Pold3 orthologs are not essential in Saccharomyces cerevisiae or chicken DT40 cells, but the Schizosaccharomyces pombe ortholog is essential. POLD3 also has a specialized role in the repair of broken replication forks, suggesting that POLD3 activity could be particularly relevant for cancer cells enduring high levels of DNA replication stress. We report here that POLD3 is essential for mouse development and is also required for viability in adult animals. Strikingly, even Pold3+/− mice were born at sub-Mendelian ratios, and, of those born, some presented hydrocephaly and had a reduced lifespan. In cells, POLD3 deficiency led to replication stress and cell death, which were aggravated by the expression of activated oncogenes. Finally, we show that Pold3 deletion destabilizes all members of the Polδ complex, explaining its major role in DNA replication and the severe impact of its deficiency., Research was funded by Fundación Botín, Banco Santander, through its Santander Universities Global Division, and by grants from the Spanish Ministry of Economy and Competitiveness (MINECO) (SAF2014-59498-R; SAF2014-57791-REDC), Fundació La Marato de TV3, the Howard Hughes Medical Institute, and the European Research Council (ERC-617840) to O.F.-C.; by a Marie Curie International Outgoing Fellowshp (IOF) from the FP7 Marie Curie Actions and a grant from MINECO (BFU2014-55168-JIN) that was co-funded by European Regional Development Funds (FEDER) to E.L.; by a grant from MINECO (BFU2013-49153) to J.M.; and by the European Commission (ERC grant ONIDDAC) to T.D.H., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A SUMO and ubiquitin code coordinates protein traffic at replication factories

  • Lecona, Emilio
  • Fernández-Capetillo, Óscar
Post-translational modifications regulate each step of DNA replication to ensure the faithful transmission of genetic information. In this context, we recently showed that deubiquitination of SUMO2/3 and SUMOylated proteins by USP7 helps to create a SUMO-rich and ubiquitin-low environment around replisomes that is necessary to maintain the activity of replication forks and for new origin firing. We propose that a two-flag system mediates the collective concentration of factors at sites of DNA replication, whereby SUMO and Ubiquitinated-SUMO would constitute “stay” or “go” signals respectively for replisome and accessory factors. We here discuss the findings that led to this model, which have implications for the potential use of USP7 inhibitors as anticancer agents., Work in OF laboratory is funded by Fundación Botín, Banco Santander,through itsSantander UniversitiesGlobalDivision and by grants from the SpanishMinistry of Economy and Competitive-ness (MINECO) (SAF2014-59498-R;SAF2014-57791-REDC), Fundaci oLa Mar-ato de TV3, Howard Hughes MedicalInstitute, and the European Research Council (ERC-617840) to OF. EL is fundedby a grant from MINECO (BFU2014-55168-JIN) that is co-funded by European Regional Development Funds (FEDER), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Targeting ATR in cancer

  • Lecona, Emilio
  • Fernández-Capetillo, Óscar
The chemical treatment of cancer started with the realization that DNA damaging agents such as mustard gas present notable antitumoural properties. Consequently, early drug development focused on genotoxic chemicals, some of which are still widely used in the clinic. However, the efficacy of such therapies is often limited by the side effects of these drugs on healthy cells. A refinement to this approach is to use compounds that can exploit the presence of DNA damage in cancer cells. Given that replication stress (RS) is a major source of genomic instability in cancer, targeting the RS-response kinase ataxia telangiectasia and Rad3-related protein (ATR) has emerged as a promising alternative. With ATR inhibitors now entering clinical trials, we here revisit the biology behind this strategy and discuss potential biomarkers that could be used for a better selection of patients who respond to therapy., Research was funded by Fundación Botín, by Banco Santander through its Santander Universities Global Division and by grants from the Spanish Ministry of Economy and Competitiveness (MINECO) (SAF2014-59498-R and SAF2014-57791-REDC); these projects were co-financed with European Regional Development funds, the Swedish Research council, Cancerfonden (CAN 2015/674) and the European Research Council (ERC-617840) to O.F.-C. and by a grant from MINECO (BFU2014-55168-JIN) that is co-funded with European Regional Development funds to E.L., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

ERF deletion rescues RAS deficiency in mouse embryonic stem cells

  • Mayor-Ruiz, Cristina
  • Olbrich, Teresa
  • Drosten, Matthias
  • Lecona, Emilio
  • Vega-Sendino, Maria
  • Ortega, Sagrario
  • Domínguez, Orlando
  • Barbacid, Mariano
  • Ruiz, Sergio
  • Fernández-Capetillo, Óscar
MEK inhibition in combination with a glycogen synthase kinase-3β (GSK3β) inhibitor, referred as the 2i condition, favors pluripotency in embryonic stem cells (ESCs). However, the mechanisms by which the 2i condition limits ESC differentiation and whether RAS proteins are involved in this phenomenon remain poorly understood. Here we show that RAS nullyzygosity reduces the growth of mouse ESCs (mESCs) and prohibits their differentiation. Upon RAS deficiency or MEK inhibition, ERF (E twenty-six 2 [Ets2]-repressive factor), a transcriptional repressor from the ETS domain family, translocates to the nucleus, where it binds to the enhancers of pluripotency factors and key RAS targets. Remarkably, deletion of Erf rescues the proliferative defects of RAS-devoid mESCs and restores their capacity to differentiate. Furthermore, we show that Erf loss enables the development of RAS nullyzygous teratomas. In summary, this work reveals an essential role for RAS proteins in pluripotency and identifies ERF as a key mediator of the response to RAS/MEK/ERK inhibition in mESCs., C.M.-R. was funded by a PhD fellowship from La Caixa Foundation, T.O. was funded by a PhD fellowship from the Boehringer Ingelheim Fonds, and S.R. was funded by a Ramon y Cajal contract (RYC-2011-09242). Research was funded by Fundación Botín and Banco Santander through its Santander Universities Global Division; grants from the Spanish Ministry of Economy and Competitiveness (SAF2011-23753 and SAF2014- 57791-REDC; these projects were cofinanced with European Fonds Européen de Développement Économique et Régional [FEDER] funds), Fundació La Marato de TV3, Howard Hughes Medical Institute, and the European Research Council (ERC- 617840) to O.F.-C.; and grants from the Spanish Ministry of Economy and Competitiveness (SAF2013-49147-P and SAF2016-80874-P; these projects were cofinanced with European FEDER funds) to S.R., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer

  • Álvarez-Fernández, Mónica
  • Sanz-Flores, María
  • Sanz-Castillo, Belén
  • Salazar-Roa, María
  • Partida, David
  • Zapatero-Solana, Elisabet
  • Raza Ali, H.
  • Manchado, Eusebio
  • Lowe, Scott
  • VanArsdale, Todd
  • Shields, David
  • Caldas, Carlos
  • Quintela-Fandino, Miguel
  • Malumbres, Marcos
PP2A is a major tumor suppressor whose inactivation is frequently found in a wide spectrum of human tumors. In particular, deletion or epigenetic silencing of genes encoding the B55 family of PP2A regulatory subunits is a common feature of breast cancer cells. A key player in the regulation of PP2A/B55 phosphatase complexes is the cell cycle kinase MASTL (also known as Greatwall). During cell division, inhibition of PP2A-B55 by MASTL is required to maintain the mitotic state, whereas inactivation of MASTL and PP2A reactivation is required for mitotic exit. Despite its critical role in cell cycle progression in multiple organisms, its relevance as a therapeutic target in human cancer and its dependence of PP2A activity is mostly unknown. Here we show that MASTL overexpression predicts poor survival and shows prognostic value in breast cancer patients. MASTL knockdown or knockout using RNA interference or CRISPR/Cas9 systems impairs proliferation of a subset of breast cancer cells. The proliferative function of MASTL in these tumor cells requires its kinase activity and the presence of PP2A-B55 complexes. By using a new inducible CRISPR/Cas9 system in breast cancer cells, we show that genetic ablation of MASTL displays a significant therapeutic effect in vivo. All together, these data suggest that the PP2A inhibitory kinase MASTL may have both prognostic and therapeutic value in human breast cancer., M.A.F. was supported by a young investigator grant from the Spanish Ministry of Economy and Competitiveness (MINECO; SAF2014-60442-JIN; co-financed by FEDER funds). M.S.F. was supported by a fellowship from the Ministry of Educación, Cultura y Deporte, and B.S.-C. was supported by Fundación La Caixa. The research described in the manuscript was funded in part by Pfizer. Work in the M.M. laboratory was supported by grants from the MINECO (SAF2012-38215), Consolider-Ingenio 2010 Programme (SAF2014-57791-REDC), Excellence Network CellSYS (BFU2014-52125-REDT), the OncoCycle Programme (S2010/BMD-2470) from the Comunidad de Madrid, Worldwide Cancer Research (WCR no. 15-0278), and the European Union Seventh Framework Programme (MitoSys project; HEALTH-F5-2010-241548)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

An E2F7-dependent transcriptional program modulates DNA damage repair and genomic stability

  • Mitxelena, Jone
  • Apraiz, Aintzane
  • Vallejo-Rodríguez, Jon
  • García-Santisteban, Iraia
  • Fullaondo, Asier
  • Álvarez-Fernández, Mónica
  • Malumbres, Marcos
  • Zubiaga, Ana
The cellular response to DNA damage is essential for maintaining the integrity of the genome. Recent evidence has identified E2F7 as a key player in DNA damage-dependent transcriptional regulation of cell-cycle genes. However, the contribution of E2F7 to cellular responses upon genotoxic damage is still poorly defined. Here we show that E2F7 represses the expression of genes involved in the maintenance of genomic stability, both throughout the cell cycle and upon induction of DNA lesions that interfere with replication fork progression. Knockdown of E2F7 leads to a reduction in 53BP1 and FANCD2 foci and to fewer chromosomal aberrations following treatment with agents that cause interstrand crosslink (ICL) lesions but not upon ionizing radiation. Accordingly, E2F7-depleted cells exhibit enhanced cell-cycle re-entry and clonogenic survival after exposure to ICL-inducing agents. We further report that expression and functional activity of E2F7 are p53-independent in this context. Using a cell-based assay, we show that E2F7 restricts homologous recombination through the transcriptional repression of RAD51. Finally, we present evidence that downregulation of E2F7 confers an increased resistance to chemotherapy in recombination-deficient cells. Taken together, our results reveal an E2F7-dependent transcriptional program that contributes to the regulation of DNA repair and genomic integrity., This work was supported by grants from the Spanish Ministry [SAF2012-33551 and SAF2015-67562-R, co-financed by FEDER funds, and SAF2014-57791-REDC], the Basque Government [IT634-13 and KK-2015/89], and the University of the Basque Country UPV/EHU [UFI11/20] to AMZ; and grants from the Spanish Ministry [SAF2015-69920-R], and Worldwide Cancer Research [15-0278] to MM. JM was recipient of a Basque Government fellowship for graduate studies and JVR is recipient of a UPV/EHU fellowship for graduate studies. M.A.F. was supported by a young investigator grant from MINECO [SAF2014-60442-JIN; co-financed by FEDER funds]. Funding for open access charge: Spanish Ministry [SAF2015-67562-R, co-financed by FEDER funds]; Basque Government [IT634-13]., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics

  • Robles, Eloy F.
  • Mena-Varas, Maria
  • Barrio, Laura
  • Merino-Cortes, Sara V.
  • Balogh, Péter
  • Du, Ming-Qing
  • Akasaka, Takashi
  • Parker, Anton
  • Roa, Sergio
  • Panizo, Carlos
  • Martin-Guerrero, Idoia
  • Siebert, Reiner
  • Segura, Victor
  • Agirre, Xabier|||0000-0002-6558-9560
  • Macri-Pellizeri, Laura
  • Aldaz, Beatriz
  • Vilas-Zornoza, Amaia|||0000-0001-6693-0989
  • Zhang, Shaowei
  • Moody, Sarah
  • Calasanz, M.J.|||0000-0002-0374-3008
  • Tousseyn, Thomas
  • Broccardo, Cyril
  • Brousset, Pierre
  • Campos-Sanchez, Elena
  • Cobaleda, Cesar|||0000-0003-3807-9204
  • Sánchez García, Isidro
  • Fernandez-Luna, Jose Luis
  • Garcia-Muñoz, Ricardo
  • Pena, Esther
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Salar Silvestre, Antonio|||0000-0002-4652-4825
  • Baptista, Maria Joao|||0000-0003-3471-2535
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
  • González, Marcos
  • Terol, Maria Jose|||0000-0002-9467-932X
  • Climent Bataller, Joan|||0000-0002-8927-6614
  • Ferrandez, Antonio
  • Sagaert, Xavier
  • Melnick, Ari M.
  • Prosper, Felipe|||0000-0001-6115-8790
  • Oscier, David G.
  • Carrasco, Yolanda R.
  • Dyer, Martin J. S.
  • Martinez-Climent, Jose A.
NKX2 homeobox family proteins have a role in cancer development. Here we show that NKX2 - 3 is overexpressed in tumour cells from a subset of patients with marginal-zone lymphomas, but not with other B-cell malignancies. While Nkx2-3 -deficient mice exhibit the absence of marginal-zone B cells, transgenic mice with expression of NKX2-3 in B cells show marginal-zone expansion that leads to the development of tumours, faithfully recapitulating the principal clinical and biological features of human marginal-zone lymphomas. NKX2-3 induces B-cell receptor signalling by phosphorylating Lyn/Syk kinases, which in turn activate multiple integrins (LFA-1, VLA-4), adhesion molecules (ICAM-1, MadCAM-1) and the chemokine receptor CXCR4. These molecules enhance migration, polarization and homing of B cells to splenic and extranodal tissues, eventually driving malignant transformation through triggering NF-κB and PI3K-AKT pathways. This study implicates oncogenic NKX2-3 in lymphomagenesis, and provides a valid experimental mouse model for studying the biology and therapy of human marginal-zone B-cell lymphomas. The homeobox NKX2 family of transcriptional factors has been shown to regulate fundamental developmental processes. Here, the authors show that NKX2-3 is a bona fide oncogenic driver in marginal-zone B-cell lymphoma and that it promotes lymphomagenesis by shaping lymphocyte dynamics and promoting BCR signalling.